drugset / Trial / NCT00442481

Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

NCT00442481

Phase 4 Unknown 25 enrolled Sheba Medical Center Lundbeck Israel · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effect of escitalopram on sleep architecture utilizing a prospective design. Hypothesis: Escitalopram will improve REM latency in patients with MDD that have responded clinically to treatment.

Timeline

Start
2007-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule